Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity

International Journal of Pharmaceutics

Volumn 337, Issue 1-2, 2007, Pages 346-356

  Pereverzeva, E ^a   Treschalin, I ^a   Bodyagin, D ^a   Maksimenko, O ^b   Langer, K ^c   Dreis, S ^c   Asmussen, B ^d   Kreuter, J ^c   Gelperina, S ^b  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^c GOETHE UNIVERSITY   (Germany)

^d LTS Lohmann Therapie Systeme AG   (Germany)

Author keywords

Cardiotoxicity; Doxorubicin; Human serum albumin; Nanoparticles; Poly(butyl cyanoacrylate); Polysorbate 80; Rat; Testicular toxicity

Indexed keywords

DOXORUBICIN; NANOPARTICLE; POLYSORBATE 80;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG FORMULATION; FOLLOW UP; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TESTIS DISEASE; TOXICOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD CELL COUNT; BODY WEIGHT; CHEMISTRY, PHARMACEUTICAL; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; ENBUCRILATE; HEART; LONG QT SYNDROME; MALE; MYOCARDIUM; NANOPARTICLES; ORGAN SIZE; POLYSORBATES; RATS; RATS, WISTAR; SERUM ALBUMIN; SURFACE-ACTIVE AGENTS; TACHYCARDIA; TESTIS; TIME FACTORS;

EID: 34248529700     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.01.031     Document Type: Article

References (38)

1. Anderlini P., Benjamin R.S., Wong F.C., Kantarjian H.M., Andreeff M., Kornblau S.M., O'Brien S., Mackay B., Ewer M.S., Pierce S.A., et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 13 (1995) 2827-2834
2. Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., Shah P., Khojasteh A., Nair M.K., Hoelzer K., Tkaczuk K., Park Y.C., and Lee L.W. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19 (2001) 1444-1454
3. Calvo P., Gouritin B., Chacun H., Desmaele D., D'Angelo J., Noel J.P., Georgin D., Fattal E., Andreux J.P., and Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18 (2001) 1157-1166
4. Colin de Verdiere A., Dubernet C., Nemati F., Soma E., Appel M., Ferte J., Bernard S., Puisieux F., and Couvreur P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer 76 (1997) 198-205
5. Couvreur P., Grislain L., Lenaerts V., Brasseur F., Guiot P., and Biernacki A. Biodegradable polymeric nanoparticles as drug carrier for antitumor agents. In: Guiot P., and Couvreur P. (Eds). Polymeric Nanoparticles and Microspheres (1986), CRC Press, Boca raton, FL 27-93
6. Couvreur P., Kante B., Grislain L., Roland M., and Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles. II. Doxorubicin-loaded nanoparticles. J. Pharm. Sci. 71 (1982) 790-792
7. Couvreur P., Kante B., Roland M., Guiot P., Bauduin P., and Speiser P. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 31 (1979) 331-332
8. Cusack B.J., Young S.P., Driskell J., and Olson R.D. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother. Pharmacol. 32 (1993) 53-58
9. Cuvier C., Roblot-Treupel L., Millot J.M., Lizard G., Chevillard S., Manfait M., Couvreur P., and Poupon M.F. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 44 (1992) 509-517
10. Danesi R., Fogli S., Gennari A., Conte P., and Del Tacca M. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin. Pharmacokinet. 41 (2002) 431-444
11. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51 (1999) 691-743
12. Gebbia N., Leto G., Gagliano M., Tumminello F.M., and Rausa L. Lysosomal alterations in heart and liver of mice treated with doxorubicin. Cancer Chemother. Pharmacol. 15 (1985) 26-30
13. Gelperina S.E., Khalansky A.S., Skidan I.N., Smirnova Z.S., Bobruskin A.I., Severin S.E., Turowski B., Zanella F.E., and Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 126 (2002) 131-141
14. Gonsette R.E. A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. Expert Opin. Pharmacother. 5 (2004) 747-765
15. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., and O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23 (2005) 7794-7803
16. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 (1999) 1564-1569
17. Hasinoff B.B., Schnabl K.L., Marusak R.A., Patel D., and Huebner E. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc. Toxicol. 3 (2003) 89-99
18. Klugmann F.B., Decorti G., Mallardi F., Klugmann S., and Baldini L. Effect of polyethylene glycol 400 on adriamycin toxicity in mice. Eur. J. Cancer Clin. Oncol. 20 (1984) 405-410
19. Kreuter J. Physicochemical characterization of polyacrylic nanoparticles. Int. J. Pharm. 14 (1983) 43-58
20. Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. Curr. Med. Chem. Central Nervous Syst. Agents 2 (2002) 241-249
21. Langer K., Balthasar S., Vogel V., Dinauer N., von Briesen H., and Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. 257 (2003) 169-180
22. Mazue G., Iatropoulos M., Imondi A., Castellino S., Brughera M., Podesta A., Della Torre P., and Moneta D. Anthracyclines: a review of general and special toxicity studies. Int. J. Oncol. 7 (1995) 713-726
23. Michaelis K., Hoffmann M.M., Dreis S., Herbert E., Alyautdin R.N., Michaelis M., Kreuter J., and Langer K. Covalent linkage of apolipoprotein E to albumin-nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 317 (2006) 1246-1253
24. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004) 185-229
25. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin. Oncol. 25 (1998) 10-14
26. Nerurkar M.M., Burto P.S., and Borchardt R.T. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13 (1996) 528-534
27. Russell L.D., and Russell J.A. Short-term morphological response of the rat testis to administration of five chemotherapeutic agents. Am. J. Anat. 192 (1991) 142-168
28. Ryberg M., Nielsen D., Skovsgaard T., Hansen J., Jensen B.V., and Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol. 16 (1998) 3502-3508
29. 2. Ann. Oncol. 11 (2000) 1029-1033
30. Shamberger R.C., Sherins R.J., Ziegler J.L., Glatstein E., and Rosenberg S.A. Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma. J. Natl. Cancer Inst. 67 (1981) 1213-1218
31. Singal P.K., Li T., Kumar D., Danelisen I., and Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol. Cell Biochem. 207 (2000) 77-86
32. Soma C.E., Dubernet C., Bentolila D., Benita S., and Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21 (2000) 1-7
33. Steiniger S.C., Kreuter J., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., Severin S.E., Uhl R., Kock M., Geiger K.D., and Gelperina S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109 (2004) 759-767
34. Tsunenari I., Kawachi M., Matsumaru T., and Katsuki S. Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 10. Testicular toxicity of adriamycin observed 2 and 4 weeks after a single intravenous administration. J. Toxicol. Sci. 25 (2000) Spec No. 103-115
35. Vauthier C., Dubernet C., Fattal E., Pinto-Alphandary H., and Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Deliv. Rev. 55 (2003) 519-548
36. Weber C., Kreuter J., and Langer K. Desolvation process and surface characteristics of HSA-nanoparticles. Int. J. Pharm. 196 (2000) 197-200
37. Woodcock D.M., Linsenmeyer M.E., Chrojnowski G., Kriegler A.B., Nink V., Webster L.K., and Sawyer W.H. Reversal of multidrug resistance by surfactants. Br. J. Cancer. 66 (1992) 62-68
38. Zucchi R., and Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr. Med. Chem. Anticancer Agents 3 (2003) 151-171